| Autor: |
Siddiqi T; City of Hope National Medical Center, Duarte, CA, USA., Coutre S; Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA, USA., McKinney M; Duke University, Durham, NC, USA., Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA., Rogers K; Ohio State University, Columbus, OH, USA., Mokatrin A; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA., Valentino R; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA., Szoke A; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA., Deshpande S; Johnson & Johnson, Raritan, NJ, USA., Zhu A; Johnson & Johnson, Raritan, NJ, USA., Arango-Hisijara I; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA., Osei-Bonsu K; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA., Wang M; The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., O'Brien S; UC Irvine, Chao Family Comprehensive Cancer Center, Irvine, CA, USA. |
| Abstrakt: |
Joint and muscle pain, including arthralgia, myalgia, and musculoskeletal pain, are among the common adverse events (AEs) reported for ibrutinib, a once-daily Bruton's tyrosine kinase inhibitor approved for the treatment of various B-cell malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). This pooled analysis from nine clinical trials of ibrutinib in CLL and MCL ( N = 1178) evaluated patterns of these AEs. Any grade arthralgia, myalgia, and musculoskeletal pain occurred in 18%, 10%, and 6% of patients, respectively. AEs were primarily low-grade (grade 1/2: 97‒99%) and occurred during the first year of treatment; most resolved (67%-80%) at first occurrence. Few (<5%) patients required ibrutinib dose modification; no patients discontinued ibrutinib due to these AEs. Among patients evaluated for concomitant medication use, all those receiving concomitant medications after the first AE occurrence experienced AE resolution. These data suggest that these AEs were not treatment-limiting during ibrutinib therapy. |
